Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Activates Genomics Deal With Hoechst AgrEvo


HAYWARD, Calif.--Lynx Therapeutics reached agreement on March 31 with Hoechst Marion Roussel and its affiliate Hoechst Schering AgrEvo to activate a subscription enabling AgrEvo to access a number of Lynx technologies. AgrEvo will pay a fee and minimum yearly subscription payments for Lynx's gene expression technologies, including Megaclone and its two derivatives, Megasort, and Massively Parallel Signature Sequencing (MPSS).

Megaclone allows simultaneous cloning of millions of DNA molecules or fragments in a sample and the parallel probing or assaying of resulting clones. Megasort is designed to extract from two related biological samples genes whose expressions differ between the samples. MPSS is designed to obtain 20 base signature sequences of nearly all genes expressed in a sample.

Lynx will receive $2 million from AgrEvo for non-exclusive access to the technologies, limited to the agricultural field. In addition, minimum subscription payments of $2 million per year will cover Lynx's costs plus profits for analyses to be performed by Lynx on behalf of AgrEvo. AgrEvo's subscription may be extended for up to three years beyond an initial one-year period.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.